SCHEMBL6085518

SCHEMBL6085518

CC(=O)NC(C)(C)Cc1cccc(-c2n[nH]cc2-c2nc3ccc(C)cc3o2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
VSIR Q9H7M9 2/20 0.42
CETP P11597 1/20 0.41
MAPT P10636 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ATM Q13315 1/20 0.41
TP53 P04637 3/20 0.40
POLB P06746 1/20 0.40
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086098 0.90 VSIR (0.39) NPC1RAB9AVSIRMAPTSMN1; SMN2
SCHEMBL6085880 0.86 NPC1 (0.39) NPC1RAB9AVSIRCETPMAPT
SCHEMBL6083677 0.81 NPC1 (0.57) NPC1RAB9ACETPMAPTSMN1; SMN2
SCHEMBL6084797 0.81 RAB9A (0.45) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL6085522 0.79 NPC1 (0.41) NPC1RAB9ACETPMAPTSMN1; SMN2
SCHEMBL6085535 0.79 NPC1 (0.59) NPC1RAB9ACETPMAPTSMN1; SMN2
SCHEMBL6083537 0.79 P2RY14 (0.61) NPC1RAB9AMAPTSMN1; SMN2HSD17B10
SCHEMBL6083980 0.77 NAMPT (0.55) NPC1RAB9ACETPMAPTSMN1; SMN2
SCHEMBL6085490 0.77 P2RY14 (0.67) NPC1RAB9AMAPTSMN1; SMN2TP53
SCHEMBL6085544 0.77 NPC1 (0.56) NPC1RAB9ACETPMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 NPC1 4031/4885RAB9A 2584/4885VSIR 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.